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Abstract
Background: The potential of mesenchymal stromal cells (MSCs) to differentiate into functional bone forming cells 
provides an important tool for bone regeneration. The identification of factors that trigger osteoblast differentiation in 
MSCs is therefore critical to promote the osteogenic potential of human MSCs. In this study, we used microarray 
analysis to identify signalling molecules that promote osteogenic differentiation in human bone marrow stroma 
derived MSCs.
Results: Microarray analysis and validation experiments showed that the expression of IGF2 and IGFBP2 was increased 
together with integrin alpha5 (ITGA5) during dexamethasone-induced osteoblast differentiation in human MSCs. This 
effect was functional since we found that IGF2 and IGFBP2 enhanced the expression of osteoblast phenotypic markers 
and in vitro osteogenic capacity of hMSCs. Interestingly, we showed that downregulation of endogenous ITGA5 using 
specific shRNA decreased IGF2 and IGFBP2 expression in hMSCs. Conversely, ITGA5 overexpression upregulated IGF2 
and IGFBP2 expression in hMSCs, which indicates tight crosstalks between these molecules. Consistent with this 
concept, activation of endogenous ITGA5 using a specific antibody that primes the integrin, or a peptide that 
specifically activates ITGA5 increased IGF2 and IGFBP2 expression in hMSCs. Finally, we showed that pharmacological 
inhibition of FAK/ERK1/2-MAPKs or PI3K signalling pathways that are enhanced by ITGA5 activation, blunted IGF2 and 
IGFBP2 expression in hMSCs.
Conclusion: The results show that ITGA5 is a key mediator of IGF2 and IGFBP2 expression that promotes osteoblast 
differentiation in human MSCs, and reveal that crosstalks between ITGA5 and IGF2/IGFBP2 signalling are important 
mechanisms that trigger osteogenic differentiation in human bone marrow derived mesenchymal stromal cells.
Background
Mesenchymal stromal cells (MSCs) can differentiate into
chondroblasts, adipocytes or osteoblasts under appropri-
ate stimulation [1-3]. Adult human MSCs (hMSCs) are
therefore an important source for tissue repair and ther-
apy in regenerative medicine [4,5]. Expanding the osteo-
genic capacity of hMSCs is thus of major interest for
improving the osteogenic potential of hMSCs for optimal
bone regeneration [6]. The osteogenic differentiation of
MSCs is characterized by the expression of timely
expressed genes such as Runx2, alkaline phosphatase
(ALP) and type I collagen (Col1A1) followed by extracel-
lular matrix mineralization [7,8]. Several hormonal and
local factors were shown to promote the osteogenic dif-
ferentiation of MSCs in vitro. Notably, short term treat-
ment with dexamethasone was found to induce the
expression of osteoblast phenotypic genes in MSCs
[9,10]. Unfortunately, glucocorticoids cannot be use ther-
apeutically to promote MSC differentiation because of
their long term negative impact on osteoblast recruit-
ment and function [11]. Therefore, identifying genes that
are induced by dexamethasone and are involved in the
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osteogenic differentiation of human MSCs may help to
promote their ability to differentiate into cells of the
osteoblast lineage.
Here, we used microarray analysis to investigate the
molecular mechanisms underlying MSC osteoblast dif-
ferentiation and enhance the osteogenic potential of
human MSCs. We report here that dexamethasone
induces the expression of IGF2 and IGFBP2 and show
that this effect triggers osteoblast differentiation in
human MSCs. We also show that this effect is mediated
by integrin alpha5 (ITGA5) expression and signalling.
Our data reveal that crosstalks between these signalling
molecules are important mechanisms that trigger osteo-
genic differentiation of human bone marrow derived
mesenchymal stromal cells.
Results
IGF2/IGFBP2 Expression is Upregulated During Osteoblast 
Differentiation of MSCs
Short term treatment with dexamethasone is known to
promote osteogenic differentiation in primary hMSCs
[9,10]. Using this differentiating system, we performed a
microarray analysis in order to gain insights into the
genes that mediate the promoting effect of dexametha-
sone on MSC osteoblast differentiation. To this goal, total
RNA from dexamethasone-treated and untreated MSCs
were collected in three different hMSC cultures and used
for microarray hybridizations using HG-U133 Plus 2.0
arrays consisting of 54,675 probesets, as described in our
original study [11]. Analysis of the normalized microarray
data revealed that there were 62, 109 and 84 probe sets
identified when selected for a fold change >2 in dexame-
thasone-treated MSCs compared to control MSCs at 1, 3
and 7 days, respectively. In this follow up study, a sub-
selection was made based on the common expression
obtained from three different donors and networks iden-
tified by the Ingenuity Software. The analysis of normal-
ized data in the three studies showed that two related
molecules, namely IGF2 and IGFBP2, as well as ITGA5
were commonly upregulated in dexamethasone-treated
MSCs compared to control MSCs at days 3 and 7 (Fig.
1A). IGF2 and IGFBP2, but not ITGA5 remained upregu-
lated at 14 days in dexamethasone-treated MSCs (data
not shown). Analysis of gene network using Ingenuity
indicated that the increased expression of IGF2, IGFBP2
and ITGA5 was inter-related (Fig. 1B). Validation experi-
ments using TaqMan Low-Density Array with two sepa-
rate experiments using mRNA from two different donors
confirmed that IGF2, IGFBP2 and ITGA5 mRNA levels
were increased by more than 2-fold in dexamethasone-
treated MSCs compared to control cells, thus validating
the microarray analysis (Fig. 2A-C). Furthermore, the
increased expression of these genes was associated with
osteoblast differentiation of hMSCs, as shown by the
increased expression of the osteoblast phenotypic genes
Runx2, ALP and COL1A1 (Fig. 2D-F). These results indi-
cate that dexamethasone-induced osteoblast differentia-
t ion in MSC s  is  c ons is t en t ly associa t ed wi t h incr eased
expression of IGF2 and IGFBP2 together with ITGA5 in
human MSCs.
IGF2/IGFBP2 promotes human MSCs osteogenic 
differentiation
Given the above results, we hypothesized that IGF2 and
IGFBP2 may be involved in MSC osteoblast differentia-
tion. To investigate the potential role of these molecules
on hMSC osteoblast differentiation, several differentia-
tion assays were conducted. We first analysed the effect
of IGF2, IGFBP2 and their combination on ALP activity,
an early marker of osteoblast differentiation. A dose
dependent effect revealed that IGF2 and IGFBP2
increased ALP activity at the dose of 2 and 0.5 nM,
respectively, whereas higher doses had no significant
Figure 1 IGF2 and IGFBP2 Expression is Up-regulated During Os-
teoblast Differentiation of hMSCs. Adult hMSCs were treated with or 
without dexamethasone (10-7M) to induce osteoblastic differentiation. 
Total RNA was collected from three different donors and used for mi-
croarray hybridization. Data were normalized and genes that were up-
regulated (fold change >2) in dexamethasone-treated compared to 
untreated MSCs were subselected (A). Analysis of gene network using 
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e f f e c t  i n  h M S C s  ( F i g .  3 A ) .  W e  t h e n  d e t e r m i n e d  t h e
effects of effective doses of IGF2, IGFBP2 and their com-
bination on osteoblast gene expression. As shown in Fig.
3B-D, we found that IGF2 or IGFBP2 at effective dosages
increased Runx2, ALP and COL1A1 mRNA levels in
hMSC, though the combination of treatment had no
additive effect. To determine whether the increased
osteoblast gene expression resulted in increased in vitro
osteogenesis, human MSCs were cultured in an osteo-
genic differentiation medium, treated with IGF2, IGFBP2
or their combination and extracellular matrix mineraliza-
tion was determined. As shown in Fig. 3E, IGFBP2 alone
or combined with IGF2 increased extracellular matrix
mineralization induced by hMSCs. Quantitative analysis
of alizarin red staining confirmed the positive effect of
IGFBP2 alone or combined with IGF2 on matrix mineral-
ization (Fig. 3F). Overall, these results show that IGF2
and IGFBP2 have a positive effect on the osteogenic dif-
ferentiation program in hMSCs.
ITGA5 Controls IGF2/IGFBP2 expression in hMSCs
Our microarray analysis (Fig. 1) revealed that IGF2,
IGBP2 and ITGA5 are upregulated during MSC osteo-
blast differentiation, suggesting possible crosstalks
between these molecules. Given our recent data indicate
that ITGA5 promotes hMSCs osteoblast differentiation
[12], we hypothesized that ITGA5 may act on MSC
osteoblast differentiation in part via up-regulation of
IGF2 and IGFBP2 in MSCs. To test this hypothesis, we
determined whether RNA interference-mediated silenc-
ing of ITGA5 expression may blunt IGF2 and IGFBP2
expression in hMSCs. As shown in Figs. 4A and 4B,
silencing of ITGA5 expression using an efficient and spe-
cific shRNA that decreases ITGA5 mRNA by 50% [12]
decreased IGF2 and IGFBP2 mRNA levels in hMSCs,
whereas a non relevant control shRNA had no effect.
Silencing of integrin β1 (ITGB1) using a specific shRNA
also decreased IGF2 and IGFBP2 mRNA levels in hMSCs,
supporting a role for the ITGA5/ITGB1 complex in IGF2
and IGFBP2 regulation in hMSCs (Figs. 4A, B). These
results indicate that ITGA5 is involved in the regulation
of IGF2 and IGFBP2 in hMSCs. To confirm this finding,
hMSCs were transduced with a lentiviral vector encoding
ITGA5 and IGF2 and IGFBP2 mRNA levels were deter-
mined. As shown in figs. 4C and 4D, ITGA5 overexpres-
sion in hMSCs increased IGF2 and IGFBP2 mRNA
Figure 2 Coordinated Upregulation of IGF2, IGFBP2 and ITGA5 During Osteoblast Differentiation in hMSCs. Adult hMSCs were treated with 
(black boxes) or without (white boxes) dexamethasone (10-7M) to induce osteoblastic differentiation and total RNA was analysed using TaqMan Low-
Density Array. IGF2, IGFBP2 and ITGA5 mRNA levels were increased by more than 2-fold in dexamethasone-treated MSCs compared to control cells 
(A-C). This was associated with increased expression of the osteoblast phenotypic genes Runx2, ALP and Col1A1 (D-F). Results are expressed as fold 
increase compared to untreated cells, after normalization to 18 S expression. The data are representative of two separate experiments using mRNA 
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expression, confirming the positive role of ITGA5 in
IGF2 and IGFBP2 expression in hMSCs.
We then determined whether activation of endogenous
ITGA5 may be sufficient to promote IGF2 and IGFBP2
mRNA expression in hMSCs. To this goal, we used a syn-
thetic peptide (CRRETAWAC) that binds and activates
ITGA5 [13]. As shown in Figs. 4C and 4D, the agonist
peptide CRRETAWAC (100 μg/ml) markedly increased
IGF2 and IGFBP2 mRNA levels in hMSCs whereas a non
relevant control peptide (GRGESP; 100 μg/ml) had no
effect. To confirm that activation of ITGA5 is sufficient to
promote IGF2 and IGFBP2 expresssion, hMSCs were
treated with a conformation-dependent anti-α5 mono-
clonal antibody (SNAKA51; 10 μg/ml) that stimulates
α5β1 integrin [13]. As shown in Figs. 4C and 4D, priming
ITGA5 using SNAKA51 increased IGF2 and IGFBP2
expresssion in hMSCs. These results provide evidence
that ITGA5 controls the expression of IGF2 and IGFBP2,
and that activation of ITGA5 using a specific monoclonal
antibody or a peptide agonist that primes this integrin is
sufficient to promote the expression of IGF2 and IGFBP2
expresssion in hMSCs.
Figure 3 IGF2/IGFBP2 Promotes Human MSCs Osteogenic Differentiation. Adult hMSCs were treated with increasing concentrations of IGF2 and 
IGFBP2 for 4 days and alkaline phosphatase activity (ALP) was determined (A). Adult hMSCs were treated with or without IGF2 (2 nM) and IGFBP2 (0.5 
nM) for 3 days, total RNA was collected and used for quantitative RT-PCR analysis of Runx2, ALP and Col1A1 expression (B-D). Adult hMSCs were cul-
tured in an osteogenic differentiation medium, treated with/without IGF2 (2 nM), IGFBP2 (0.5 nM) or their combination and extracellular matrix min-
eralization was evaluated by alizarin red staining (E) and confirmed by quantification (F). Results are expressed as the mean ± SD of treated over control 
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Inhibition of ITGA5-induced signalling abrogates IGF2/
IGFBP2 expression in hMSCs
We then determined the signalling mechanisms underly-
ing the promoting effect of ITGA5 on IGF2 and IGFBP2
expression in hMSCs. Integrins are known to activate
various signalling pathways, including FAK [14]. We thus
hypothesized that FAK and downstream signalling path-
ways may mediate the increased IGF2 and IGFBP2
expresssion induced by ITGA5 in hMSCs. To test this
hypothesis, hMSCs were transfected with a specific
shRNA that effectively decreases FAK protein level by
60% [12]. As shown in Figs. 5A and 5B, the expresssion of
IGF2 and IGFBP2 mRNA was decreased in shFAK-trans-
fected cells. Furthermore, FAK silencing abolished IGF2
and IGFBP2 expression induced by LV-ITGA5 or CRRE-
TAWAC (Figs. 5A and 5B). These results reveal a key role
for FAK signaling in ITGA5-induced IGF2 and IGFBP2
expression in hMSCs. To further investigate the role of
downstream pathways, hMSCs were treated with the
MEK inhibitor U0126, or wortmannin, a specific PI3K
inhibitor. As shown in Figs. 5C and 5D, pharmacological
inhibition of MEK or PI3K markedly decreased IGF2 and
IGFBP2 expresssion in hMSC. These results indicate that
these pathways act downstream of ITGA5/FAK signalling
to regulate IGF2 and IGFBP2 expression in hMSCs.
Figure 4 ITGA5 Controls IGF2/IGFBP2 Expression in hMSCs. Adult hMSCs were transduced with shITGA5, shITGB1 or a non relevant shRNA (shNR), 
total RNA was used for quantitative RT-PCR analysis of IGF2 (A) and IGFBP2 (B). Adult hMSCs were transduced with a lentiviral vector encoding ITGA5, 
or treated with the agonist peptide CRRETAWAC (100 μg/ml) (CRRETAWAC) or with a non relevant control peptide (GRGESP; 100 μg/ml), or with a 
conformation-dependent anti-α5 monoclonal antibody (SNAKA51; 10 μg/ml), and IGF2 and IGFBP2 mRNA expression was determined by quantitative 
RT-PCR analysis (C-D). Results are expressed as mean ± SD of treated over control ratio after normalization to 18 S expression. *: significant difference 
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Overall, the results support a mechanism by which dex-
amethasone-induced ITGA5 expression, or activation of
ITGA5 signalling promote IGF2 and IGFBP2 expression
which thereby results in activation of osteoblast gene
expression in human primary MSCs. This reveals that
novel crosstalks between these signalling molecules are
important mechanisms that trigger osteogenic differenti-
ation in human mesenchymal stromal cells (Fig. 6).
Discussion
Finding mechanisms that trigger osteogenic differentia-
tion of hMSCs may help developing novel therapeutic
approaches to promote bone formation. In this study, we
demonstrate that previously unidentified crosstalks
between ITGA5, IGF2 and IGFBP2 are functionally
involved in osteoblast differentiation of human MSCs.
We first established by microarray analysis that dexame-
thasone-induced osteoblast differentiation in hMSCs is
associated with up-regulation of IGF2 and IGFBP2, sug-
gesting that these molecules are involved in dexametha-
sone-induced osteoblast differentiation [15]. IGF2 was
also found to be up-regulated in dental stem cells during
osteogenic differentiation [16], and similar gene expres-
sion profiles of IGF2 and BMP2 were reported in differ-
entiated dental follicle cells [17], suggesting an important
role of IGF2 in osteogenic differentiation. However, the
actions of IGFs and IGFBPs on osteoblastic cells are com-
plex [18,19]. Both IGFs and IGFBPs are expressed by
osteoblasts in vivo and in vitro [20,21]. IGF2 was found to
promote ALP activity or collagen synthesis in differenti-
ated osteoblasts [18,22] and IGFBP2 levels were shown to
increase during osteoblast differentiation [23]. However,
Figure 5 Inhibition of ITGA5-Induced Signalling Abrogates IGF2/IGFBP2 Expression in hMSCs. Adult hMSCs transduced with a lentiviral vector 
encoding ITGA5 or treated with the agonist peptide (CRRETAWAC; 100 μg/ml), and control cells were transiently transfected with a specific shRNA 
targeting FAK. Total RNA was collected and used for quantitative RT-PCR analysis of IGF2 (A) and IGFBP2 (B). Adult hMSCs were treated with the MEK 
inhibitor U0126 (10 μM), or the PI3K inhibitor wortmannin (50 nM) for 24 hours and IGF2 and IGFBP2 mRNA levels were determined by quantitative 
RT-PCR analysis (C-D). Results are expressed as mean ± SD of treated over control ratio after normalization to 18 S expression. *: significant difference 
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little is known on the role of IGF2 and IGFBP2 in the
early stages of osteoblastogenesis. We show here that
IGF2 and IGFBP2 are functionally involved in the osteo-
genic differentiation of human mesenchymal stromal
cells. Indeed, we found that IGF2/IGFBP2 at low doses
increased the expression of osteoblast phenotypic genes
and in vitro osteogenic capacity of hMSCs. The previ-
ously unrecognised positive role of IGF2/IGFBP2 on
osteogenic differentiation of hMSCs in vitro suggests that
these molecules may be anabolic in vivo. This is sup-
ported by the finding that subcutaneous administration
of IGF2/IGFBP2 stimulates bone formation and prevents
b o n e  l o s s  i n  o s t e o p e n i c  r a t s  [ 2 4 ] .  A  p o s i t i v e  r o l e  f o r
IGFBP2 in bone formation and trabecular bone acquisi-
tion has also been reported in mice [25]. This anabolic
effect is consistent with the recent finding that IGF2 and
IGFBP2 levels and bone formation are increased in
patients with osteosclerosis linked to hepatitis C [26].
The present study revealing that IGF2/IGFBP2 triggers
human MSC osteoblast differentiation provides one cel-
lular mechanism that may account for the positive effect
of IGF2/IGFBP2 on osteoblastogenesis and bone forma-
tion.
Several lines of evidence point to functional links
between IGF2 and IGFBP2 and ITGA5 in hMSCs. First,
we found that ITGA5 silencing reduced IGF2 and
IGFBP2 expression. Second, we showed that ITGA5 over-
expression up-regulated IGF2 and IGFBP2, indicating
that ITGA5 acts upstream of IGF2 and IGFBP2 in
hMSCs. Third, specific activation of ITGA5 using an
anti-ITGA5 monoclonal antibody that primes the integ-
rin, or a peptide that acts as an ITGA5 agonist promoted
IGF2 and IGFBP2 expression in hMSCs, further demon-
strating that ITGA5 signalling plays a key role in the regu-
lation of IGF2 and IGFBP2 in hMSCs. Integrins have
been previously found to interact with IGFBP2 in cancer
cells [27,28]. Whether ITGA5 may directly interact with
IGFBP2 to trigger cell signalling and osteogenic differen-
tiation in hMSCs is an interesting possibility that remains
to be determined. One mechanism by which ITGA5 may
a ct iva t e  IG F2 and IG FB P2 e x pr ess ion in hMSCs  is  via
activation of signalling pathways that are activated by
ITGA5. Interestingly, our data showed that FAK, ERK1/2
and PI3K that are all activated by ITGA5 [29] mediate the
increased IGF2 and IGFBP2 expression in hMSCs. These
data provide novel mechanisms by which activation of
ITGA5 and downstream FAK, ERK1/2 and PI3K signal-
ling upregulates autocrine IGF2/IGFBP2 expression and
thereby promotes osteoblast differentiation in human
mesenchymal stromal cells.
Conclusions
The present study identifies a sequence of molecular
mechanisms by which ITGA5 expression or activation
and downstream activation of FAK, ERK1/2 and PI3K
signalling induce IGF2/IGFBP2 expression in hMSCs.
Furthermore, this study reveals novel crosstalks between
ITGA5 and IGF2/IGFBP2 signalling that converge to
induce osteoblast differentiation in hMSCs (Fig. 6). These
mechanisms may help designing novel therapeutic strate-
gies for promoting the osteogenic differentiation poten-
tial of human mesenchymal stromal cells.
Methods
Mesenchymal Stromal Cells
Human primary mesenchymal stromal cells (hMSCs)
were obtained from bone marrow aspirates (iliac crest) of
patients undergoing hip replacement surgery. Informed
consent from each patient was obtained before surgery
[30] according to the French regulation. Cells were cul-
tured in Dulbecco's Modified Eagle's Medium (DMEM;
Invitrogen Corporation, Paisley, Scotland) supplemented
with 10% heat inactivated Fetal Calf Serum (FCS; PAA
Laboratories, Les Mureaux, France), L-glutamine (292
mg/l) and antibiotics (10,000 U/ml penicillin and 10,000
μg/ml streptomycin) at 37°C in a humidified atmosphere
containing 5% CO2 in air. Cells were expanded and used
at passage 2.
Materials
The lentiviral vector encoding complete sequence of
ITGA5 was obtained as previously described [29]. Two
different shRNA species were tested. The data shown are
representative of the most effective shRNA. Non relevant
shRNA (scrambled sequence that does not lead to spe-
Figure 6 Proposed Model by which Crosstalks Between ITGA5 
and IGF2/IGFBP2 Signalling Trigger Osteogenic Differentiation in 
Human MSCs. ITGA5 expression induced by dexamethasone or ITGA5 
activation by agonists upregulate signalling pathways that activate 
IGF2/IGFBP2 expression in hMSCs which in turn triggers osteoblast dif-
ferentiation, revealing that ITGA5 and IGF2/IGFBP2 crosstalks are im-
portant mechanisms controlling osteogenic differentiation in human 
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cific degradation of any known cellular mRNA), ITGB1
shRNA and human FAK shRNA lentiviral particles (mix-
tures of viral particles containing 3 target-specific con-
structs that encode shRNA designed to knock down gene
expression) were obtained from Santa Cruz Biotechnol-
ogy (Heidelberg, Germany). Western blot analysis
showed that gene expression was effectively down-regu-
lated using these gene specific shRNAs (12). The ITGA5
activating monoclonal antibody (SNAKA51) and the syn-
thetic agonist peptide (CRRETAWAC) were kindly pro-
vided by Dr. M.J. Humphries (University of Manchester,
UK). A rabbit IgG fraction (negative control) was from
Dako (Trappes, France). The synthetic control peptide
(GRGESP, used as control for CRRETAWAC in USA Pat-
ent Number 5,627,263 by E. Ruoslahti and E. Koivunen,
1997) was from Peptide 2.0 Inc (Chantilly, VA, USA). The
pharmacological inhibitors U0126 and Wortmannin were
from Sigma-Aldrich (St. Louis, MI, USA).
Microarray Analysis
Subconfluent human MSCs were incubated with or with-
out 10-7 M dexamethasone for 1, 3 or 7 days, and total
RNA was isolated using an RNeasy kit (Qiagen, Courta-
boeuf, France) according to the manufacturer's recom-
mendations. Gene expression profiling with Affymetrix
HG-U133 Plus 2.0 arrays was performed in three differ-
ent studies using primary human MSCs from different
donors as described in our previous original study [11].
Briefly, cDNA was synthesized from 1 μg of total RNA
and transcribed into biotin-labelled cRNA. Fifteen
micrograms of fragmented cRNA per 300 μl were then
hybridized to the GeneChips for 16 h at 45°C. Hybridiza-
tion was performed according to the standard Affymetrix
protocol. GeneChips were washed, stained and scanned
with the GeneArray scanner controlled by Affymetrix
GCOS software. Raw gene expression data were pro-
cessed with the GCOS 1.2 software for signal calculation.
Comparison analysis and cellular pathways were analyzed
using statistical tools (http://www.bioretis.de; http://
www.ingenuity.com/index.html). The microarray data are
available on line http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE18043.
Quantitative RT-PCR Analyses
Total RNA was isolated using RNeasy Kit (Qiagen)
according to the manufacturer's recommendations.
cDNA synthesis was performed using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems).
Each reaction containing 3 μg of total RNA, 1× RT buffer,
1 mM dNTP mix, 1× random primers and 50 U multi-
scribe reverse transcriptase in a total volume of 100 μl.
The reverse transcription reactions were run under the
following conditions: 25°C for 5 min, 37°C for 120 min
and 95°C for 2 minutes. Products of reverse transcription
were analysed either on a predesigned TaqMan Low-
Density Array (sets for 47 human genes and GAPDH
RNA as a reference gene) based on an Applied Biosys-
tems 7900HT 384-well format Microfluidic Card, or by
quantitative PCR using LightCycler (Roche Applied Sci-
ence, Indianapolis Ind., USA) and SYBR Green PCR kit
(ABGen, Courtabœuf, France), as previously described
[29].
Alkaline Phosphatase Activity
Cells were lyzed and sonicated in ice cold H2O. Lysates
were centrifuged at 3500 rpm for 15 min at 4°C and ALP
activity was determined using the Alkaline Phosphatase
kit (BioRad; Hercules, USA) as previously described [31].
Total protein content was determined using BioRad
reagent (BioRad). In parallel, cell monolayers were fixed
in ethanol (70%) before ALP activity cytochemical detec-
tion using Sigma FAST BCIP/NBT kit. Wells were micro-
photographed using an Olympus microsocope Japan).
Osteogenic Assay
For in vitro matrix mineralization, the medium was sup-
plemented with ascorbic acid (50 μg/ml) and inorganic
phosphate (NaH2PO4; 3 mM) to induce collagenous
matrix synthesis and mineralization [32]. After 14 days of
culture, cells were fixed in 4% paraformaldehyde in PBS.
Matrix mineralization was detected by alizarin red stain-
ing (40 mM, pH 4.2) and microphotographed using an
Olympus microsocope (Japan). Alizarin red content was
quantified spectrophotometrically after dissolution in
cetylpyridinium chloride (10% in PBS).
Statistical Analysis
The results are expressed as mean ± SD of at least 3 sam-
ples. Comparisons between data were performed using
the two-factor analysis of variance (ANOVA) using the
statistical package super-ANOVA (Macintosh, Abacus
concepts, Inc., Berkeley, CA). A minimal level of P < 0.05
was considered significant.
Abbreviations
(ALP): Alkaline phosphatase; (Col1A1): Type I collagen; (ERK1/2): Extracellular-
related kinases 1 and 2; (FAK): Focal adhesion kinase; (ITGA5): Integrin alpha 5;
(ITGB1): Integrin beta I; (MAPK): Mitogen-activated protein kinases; (MSCs):
Mesenchymal stromal cells; (PI3K): Phosphatidylinostol 3-kinase.
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